Search hospitals

>

Missouri

>

Cape Girardeau

Saint Francis Medical Center

Claim this profile

Cape Girardeau, Missouri 63703

Global Leader in Cancer

Global Leader in Lung Cancer

Conducts research for Breast Cancer

Conducts research for Breast cancer

Conducts research for Non-Small Cell Lung Cancer

430 reported clinical trials

5 medical researchers

Photo of Saint Francis Medical Center in Cape GirardeauPhoto of Saint Francis Medical Center in Cape GirardeauPhoto of Saint Francis Medical Center in Cape Girardeau

Summary

Saint Francis Medical Center is a medical facility located in Cape Girardeau, Missouri. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Saint Francis Medical Center is involved with conducting 430 clinical trials across 471 conditions. There are 5 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, Robert H. Stone, RRT, and Stephen S. Bricknell, RRT.

Area of expertise

1

Cancer

Global Leader

Saint Francis Medical Center has run 104 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 negative
2

Lung Cancer

Global Leader

Saint Francis Medical Center has run 75 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Saint Francis Medical Center

Bladder Cancer

Lung Cancer

Prostate Cancer

Cancer

Kidney Cancer

Breast cancer

Breast Cancer

Bladder Carcinoma

Non-Small Cell Lung Cancer

Ovarian Cancer

Image of trial facility.

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Pembrolizumab + Sacituzumab Govitecan

for Urothelial Cancer

This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan. Sacituzumab attaches to TROP2 positive tumor cells in a targeted way and delivers govitecan to kill them. The usual treatment approach is treatment with chemotherapy such as cisplatin, carboplatin, gemcitabine, docetaxel or paclitaxel. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Giving pembrolizumab and sacituzumab govitecan may be more effective than usual care of carboplatin or cisplatin with gemcitabine, docetaxel or paclitaxel in treating patients with locally advanced or metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

17 criteria

Image of trial facility.

Shorter Duration Radiation Therapy

for Bladder Cancer

This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine or mitomycin and 5-fluorouracil for the treatment of patients with muscle invasive bladder cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a short period of time. Ultra-hypofractionated radiation therapy delivers radiation over an even shorter period of time than hypofractionated radiation therapy. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Chemotherapy drugs, such as mitomycin-C and 5-fluorouracil (5-FU), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ultra-hypofractionated radiation may be equally effective as hypofractionated therapy for patients with muscle invasive bladder cancer.

Recruiting

2 awards

Phase 3

7 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Saint Francis Medical Center?

Where is Saint Francis Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Saint Francis Medical Center accept?

What awards or recognition has Saint Francis Medical Center received?